Vaginal Adventitia Reserved and Anatomical Implant Technique of Transvaginal Mesh Procedure for Pelvic Organ Prolapse

Sponsor
West China Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05707533
Collaborator
(none)
589
1
4
148.2

Study Details

Study Description

Brief Summary

After obtaining an institutional ethics approval (#2021833), the investigators retrospectively reviewed patients with Pelvic organ prolapse (POP) who underwent Transvaginal Mesh (TVM) in their hospital during June 2008 and December 2020. The goal of this observational study is to introduce the Vaginal Adventitia Reserved and Anatomical Implant Technique in Transvaginal mesh surgery, and to report long term efficacy and safety results of this technique. The main questions it aims to answer are:

  • How to reduce the potential risk of mesh-related complications when performing TVM?

  • How effective is the use of the Vaginal Adventitia Reserved and Anatomical Implant Technique when performing TVM? Participants will be asked to fill the Pelvic Floor Distress Inventory (PFDI-20) at final follow-up, and the Prosthesis/Graft Complication Classification Code was used to record the mesh-related complications.

Condition or Disease Intervention/Treatment Phase
  • Procedure: TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique

Detailed Description

Patients and materials The investigators retrospective reviewed consecutive patients with stage II to IV Pelvic organ prolapse (POP) who underwent Transvaginal Mesh (TVM) at their center from June 2008 to December 2020. The Vaginal Adventitia Reserved and Anatomical Implant Technique was performed on all patients. Informed consent was obtained from all included patients. Approval was obtained from the institutional ethics committee of our hospital (West China Hospital, Sichuan University).

The pre-cut mesh kits including Gynecare Prolift® (Ethicon, Sommerville, NJ, USA), Perigee (AMS, Minnetonka, MN, USA), and Gynecare Prosima® (Ethicon, Sommerville, NJ, USA) and self-cut mesh Gynemesh (Ethicon, Sommerville, NJ, USA) were applied for transvaginal mesh repair in this study. Surgery was performed by an experienced surgeon (Dr. HS), utilizing the vaginal adventitia reserved and anatomical implant technique.

Outcome measures The effect of operation was assessed using both objective and subjective measures. The objective assessment (anatomic assessment) of success was that the nadir of prolapse never reached the point 0 (the level of hymen). The subjective assessment of success was the absence of prolapse symptoms. Chinese version of the Pelvic Floor Distress Inventory (PFDI-20) was also utilized for assessing the outcomes. Prosthesis/Graft Complication Classification Code was used to record the mesh-related complications.

Data analysis Statistical analysis was performed via the commercially available statistical package (SPSS) 22.0 for Windows (SPSS, Chicago, IL, USA). Categorical variables were represented using frequency and percentages and compared using the chi-square test. Continuous variables in accord with normal distribution were described using means and standard deviations (SDs) and analyzed using the Student's t-test. Statistical significance was defined at P < 0.05.

Study Design

Study Type:
Observational
Actual Enrollment :
589 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Vaginal Adventitia Reserved and Anatomical Implant Technique of Transvaginal Mesh Procedure for Pelvic Organ Prolapse: 13-year Surgical Results With 589 Cases
Actual Study Start Date :
Aug 1, 2022
Actual Primary Completion Date :
Nov 30, 2022
Actual Study Completion Date :
Nov 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Patients underwent TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique

Patients with pelvic organ prolapse who underwent TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique between June 2008 and December 2020

Procedure: TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique
The Transvaginal mesh procedure with Vaginal Adventitia Reserved and Anatomical Implant Technique for the treatment of POP. The Cefoxitin Injection Solution was used for Prophylactic antibiotics
Other Names:
  • Cefoxitin
  • Outcome Measures

    Primary Outcome Measures

    1. Pelvic Organ Prolapse-Quantification (POP-Q) scores [The time frame was from the date of surgery to the date of final follow-up, ranging from 9 to 156 months.]

      The POP-Q system was used to assess the pelvic organ prolapse

    2. complication [The time frame was from the date of surgery to the date of final follow-up, ranging from 9 to 156 months.]

      Prosthesis/Graft Complication Classification Code was used to record the mesh-related complications

    3. Pelvic Floor Distress Inventory (PFDI-20) scores [The time frame was from the date of surgery to the date of final follow-up, ranging from 9 to 156 months.]

      The PFDI-20 was used to assess pelvic floor symptoms and associated bother and has 3 subscales: the pelvic organ prolapse distress inventory (POPDI)(0-300); the colorectal-anal distress inventory (CRADI)(0-400); and the urinary distress inventory (UDI)(0-300). Higher scores indicted greater symptom bother.

    4. Female Sexual Function Index (FSFI) scores [The time frame was from the date of surgery to the date of final follow-up, ranging from 9 to 156 months.]

      FSFI was used to assess the sexual function, which was a validated questionnaire comprised of 19 items. FSFI's total score ranged from 2 to 36; the higher the score, the severer the sexual dysfunction.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age >18 yr

    • Clinical diagnosis of pelvic organ prolapse

    • Pelvic organ prolapse-quantification (POP-Q) > II stage

    • Patients underwent TVM using the Vaginal Adventitia Reserved and Anatomical Implant Technique

    Exclusion Criteria:
    • Patients who refused to participate in the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 West China Hospital Chengdu Sichuan China 610041

    Sponsors and Collaborators

    • West China Hospital

    Investigators

    • Study Chair: Wei-min Li, PhD., West China Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    De-yi Luo, Prof., West China Hospital
    ClinicalTrials.gov Identifier:
    NCT05707533
    Other Study ID Numbers:
    • 2021833
    First Posted:
    Feb 1, 2023
    Last Update Posted:
    Feb 1, 2023
    Last Verified:
    Jan 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by De-yi Luo, Prof., West China Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 1, 2023